Hanall Biopharma

At a glance

Hanall Biopharma filed 44 disclosures in the last 12 months, including 6 insider, 4 earnings, 3 5% holder and 3 buyback. The most recent key filing was on Oct 28: Operating profit ₩1.3B, up 265% YoY. Revenue ₩39.9B, down 2.2% YoY.

Revenue for 2025 was ₩155B, up 11.7% on 2024. It made an operating loss of ₩915.8M. Debt was 39% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩84.3B and operating profit of ₩6.4B.

The 2025 annual report lists 315 employees with an average tenure of 15.1 years and average pay of ₩82M, #337 of 1,829 listed companies by average pay. Its 7 directors and auditors were paid ₩213.8M each on average. It paid no cash dividend for 2025. (주)대웅제약 and related parties held 31.20% at year end.

From the 2025 annual report

Staff: 315 (211 men, 104 women), of whom 14 on fixed-term contracts. Total pay for the year: ₩25.9B. Directors and auditors: 7, paid ₩1.5B in total.

No cash dividend was paid for 2025.

Largest shareholder

(주)대웅제약 holds 30.80%; with 3 related parties the group holds 31.20% of common shares at year end (from 31.00% at the start of the year).

Individuals paid ₩500M or more

Auditor: 한영회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary